Literature DB >> 29158067

Psoas Muscle Area as a Prognostic Factor for Survival in Patients with an Asymptomatic Infrarenal Abdominal Aortic Aneurysm: A Retrospective Cohort Study.

Reza Indrakusuma1, Jendé L Zijlmans2, Hamid Jalalzadeh2, R Nils Planken3, Ron Balm2, Mark J W Koelemay3.   

Abstract

OBJECTIVES: Loss of muscle mass has been associated with poor survival in several surgical patient populations, including those with an abdominal aortic aneurysm (AAA). We wanted to replicate these findings and assess the association between psoas muscle area (PMA) and survival in patients with an asymptomatic AAA.
METHODS: Patients with an asymptomatic infrarenal AAA who underwent computed tomography (CT) scanning between January 1, 2007, and December 31, 2013, were included in this single-centre retrospective cohort study. PMA was measured with thresholding on an axial image at the centre level of the third lumbar vertebra. The lowest tertile of PMA in all patients was used as a cutoff value for a low PMA. Then, in separate analyses for conservatively and surgically managed patients, survival was estimated with the Kaplan-Meier method. Differences in survival between patients with and without a low PMA were tested with the log-rank test.
RESULTS: Of 228 patients, 104 were managed conservatively and 124 underwent AAA repair. Seventy-seven patients (62%) had an endovascular repair. In these 228 patients, the median PMA was 16.83 cm2, while the cutoff value for low PMA was 14.56 cm2. Patients who were managed conservatively were more often classified as having low PMA (45/104, 43%, vs. 31/124, 25%; p = .004) and were significantly older (mean 73.44 ± 9.05 years vs. 69.03 ± 7.46 years; p < .001). Low PMA was not associated with survival, either in patients managed conservatively, or in those who underwent AAA repair (p = .512 and p = .311, respectively).
CONCLUSIONS: The association between low PMA and poor survival could not be replicated; in this study, low PMA was not associated with survival in patients with an asymptomatic AAA. Further research is recommended before PMA can be used for pre-operative risk stratification.
Copyright © 2017 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Abdominal aortic aneurysm; Frailty; Mortality; Psoas muscle area; Survival

Mesh:

Year:  2017        PMID: 29158067     DOI: 10.1016/j.ejvs.2017.10.007

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  5 in total

1.  Adverse Outcomes after Advanced EVAR in Patients with Sarcopaenia.

Authors:  Abdullah O Alenezi; Elizabeth Tai; Arash Jaberi; Andrew Brown; Sebastian Mafeld; Graham Roche-Nagle
Journal:  Cardiovasc Intervent Radiol       Date:  2021-01-03       Impact factor: 2.740

2.  The association of body composition with abdominal aortic aneurysm growth after endovascular aneurysm repair.

Authors:  Ge Hu; Ning Ding; Zhiwei Wang; Zhengyu Jin
Journal:  Insights Imaging       Date:  2022-04-25

3.  Stent-graft surface movement after endovascular aneurysm repair: baseline parameters for prediction, and association with migration and stent-graft-related endoleaks.

Authors:  Ulrika Asenbaum; Maria Schoder; Ernst Schwartz; Georg Langs; Pascal Baltzer; Florian Wolf; Alexander M Prusa; Christian Loewe; Richard Nolz
Journal:  Eur Radiol       Date:  2019-06-27       Impact factor: 5.315

4.  Impact of sarcopenia in aortoiliac occlusive disease in Mediterranean population.

Authors:  António Pereira-Neves; Daniela Barros; João Rocha-Neves; Luís Duarte-Gamas; Marina Dias-Neto; Alfredo Cerqueira; José Vidoedo; José Teixeira
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2020-10-21       Impact factor: 0.332

5.  Impact of Sarcopenia on Acute Kidney Injury after Infrarenal Abdominal Aortic Aneurysm Surgery: A Propensity Matching Analysis.

Authors:  Ji-Yeon Bang; In-Gu Jun; Jeong-Bok Lee; You-Sun Ko; Kyung-Won Kim; Jun-Hyeop Jeong; Sung-Hoon Kim; Jun-Gol Song
Journal:  Nutrients       Date:  2021-06-27       Impact factor: 5.717

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.